Since the start of September, the luster has disappeared from Exact Sciences' stock. This pullback provides an opportunity to own a company that is growing on multiple levels.
News & Analysis: Exact Sciences
Shares are heading in opposite directions after the two cancer diagnostic companies surprised Wall Street by revealing plans to merge. Here's what investors need to know.
The biotech's recent momentum is showing no signs of cooling off, despite its jaw-dropping valuation.
Exact Sciences stock hit an all-time high last month, despite a sour market for biotech stocks.
Worries about Obamacare have taken a toll on shares of the diagnostics test company.
The diagnostics company's new marketing partner appears to be pulling its weight.
Shares of the molecular diagnostics company reverted to the mean last month, perhaps creating a tremendous buying opportunity for aggressive investors.
The molecular-diagnostics company's early look at Q4 and full-year 2018 revenue numbers revved up investors.
Shares jump after the company reports upbeat third-quarter results. Here's what investors need to know.
Exact Sciences' stock got a major boost from a partnering deal with pharma titan Pfizer last month.
The company's deal with Pfizer to co-promote the Cologuard colorectal cancer test continues to excite investors.